CNS Pharmaceuticals Inc. held its Annual Meeting of Stockholders on November 17, 2025. Shareholders approved amendments to the company's 2020 Equity Plan, increasing the number of shares authorized for issuance under the plan. The meeting also saw the election of John Climaco, Jerzy (George) Gumulka, Jeffry R. Keyes, Faith Charles, Bettina Cockroft, and Amy Mahery to the board of directors. In addition, shareholders approved amendments to the company's Articles of Incorporation to increase the total number of authorized shares of common stock from 25,000,000 to 300,000,000 and the total number of authorized shares of preferred stock from 416,667 to 5,000,000.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CNS Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001683168-25-008624), on November 21, 2025, and is solely responsible for the information contained therein.